FTC Requires Abbott Laboratories to Divest Two Types of Point-Of-Care Medical Testing Devices as Condition of Acquiring Alere Inc.

Abbott Laboratories and Alere Inc. have agreed to a divestiture of two point-of-care medical device products line in order to settle Federal Trade Commission charges that Abbott’s proposed $8.3 billion acquisition of Alere will cause harm to competition. Abbott is a global healthcare company that produces, among other things, point-of-care diagnostic devices designed for use […]

FTC Requires Divestiture of 5 Medical Device Product Lines as Condition of Integra Acquiring Johnson & Johnson’s Codman Neuro Division

Integra LifeSciences Holdings Corp. and Johnson & Johnson have agreed to a divestiture of five neurosurgical medical device product lines to settle Federal Trade Commission charges that Integra’s proposed $1 billion acquisition of Johnson & Johnson’s Codman Neuro division would negatively impact competition in those markets. Both companies supply a range of  devices used in […]

FTC Approves Final Order Preserving Competition in U.S. Markets for Medical Devices Used in Cardiac and Vascular Catheterization

Following a public comment period, the Federal Trade Commission has approved a final order settling charges that Abbott Laboratories’ $25 billion acquisition of St. Jude Medical, Inc. would likely be anticompetitive. First announced in December 2016, the FTC’s complaint alleged that as proposed, the acquisition would likely harm competition in the U.S. markets for vascular […]